Skip to main content
×
Home
    • Aa
    • Aa

Molecular basis of iron-loading disorders

  • Deepak Darshan (a1), David M. Frazer (a1) and Gregory J. Anderson (a1)
Abstract

Iron-loading disorders (haemochromatosis) represent an important class of human diseases. Primary iron loading results from inherited disturbances in the mechanisms regulating intestinal iron absorption, such that excess iron is taken up from the diet. Body iron load can also be increased by repeated blood transfusions (secondary iron loading), usually as part of the treatment for various haematological disorders. In these syndromes, an element of enhanced iron absorption is also often involved. The central regulator of body iron trafficking is the liver-derived peptide hepcidin. Hepcidin limits iron entry into the plasma from macrophages, intestinal enterocytes and other cells by binding to the sole iron-export protein ferroportin, and facilitating its removal from the plasma membrane. Mutations in hepcidin or its upstream regulators (HFE, TFR2, HFE2 and BMP6) lead to reduced or absent hepcidin expression and a concomitant increase in iron absorption. Mutations in ferroportin that prevent hepcidin binding produce a similar result. Increased ineffective erythropoiesis, which often characterises erythrocyte disorders, also leads to reduced hepcidin expression and increased absorption. Recent advances in our understanding of hepcidin and body iron homeostasis provide the potential for a range of new diagnostic and therapeutic tools for haemochromatosis and related conditions.

Copyright
Corresponding author
*Corresponding author: Gregory J. Anderson, Iron Metabolism Laboratory, Queensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. E-mail: greg.anderson@qimr.edu.au
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1 M.B. Zimmermann and R.F. Hurrell (2007) Nutritional iron deficiency. Lancet 370, 511-520

2 J. O'Neil and L. Powell (2005) Clinical aspects of hemochromatosis. Seminars in Liver Disease 25, 381-391

3 P.L. Lee and E. Beutler (2009) Regulation of hepcidin and iron-overload disease. Annual Review of Pathology 4, 489-515

5 G. Rechavi and S. Rivella (2008) Regulation of iron absorption in hemoglobinopathies. Current Molecular Medicine 8, 646-662

9 A.T. McKie (2001) An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291, 1755-1759

10 M.D. Fleming (1998) Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proceedings of National Academy of Sciences USA 95, 1148-1153

11 H. Gunshin (1997) Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388, 482-488

12 S. Abboud and D.J. Haile (2000) A novel mammalian iron-regulated protein involved in intracellular iron metabolism. Journal of Biological Chemistry 275, 19906-19912

14 A.T. McKie (2000) A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Molecular Cell 5, 299-309

17 M.E. Conrad , L.R. Weintraub and W.H. Crosby (1964) The role of the intestine in iron kinetics. Journal of Clinical Investigation 43, 963-974

18 D.M. Frazer (2003) A rapid decrease in the expression of DMT1 and Dcytb but not Ireg1 or hephaestin explains the mucosal block phenomenon of iron absorption. Gut 52, 340-346

19 H. Chen (2003) Systemic regulation of hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 102, 1893-1899

21 G.J. Anderson (2007) Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals 20, 665-674

22 A. Donovan (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism 1, 191-200

23 E. Nemeth and T. Ganz (2009) The role of hepcidin in iron metabolism. Acta Haematologica 122, 78-86

24 E. Nemeth (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation 113, 1271-1276

25 K.J. Allen (2008) Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine 358, 221-230

26 J.V. Neves Hemochromatosis and pregnancy: iron stores in the Hfe-/- mouse are not reduced by multiple pregnancies. American Journal of Physiology Gastrointestinal and Liver Physiology 298, G525-G529

27 B. Benyamin (2009) Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. American Journal of Human Genetics 84, 60-65

28 D. Galaris and K. Pantopoulos (2008) Oxidative stress and iron homeostasis: mechanistic and health aspects. Critical Reviews in Clinical Laboratory Sciences 45, 1-23

29 G.A. Ramm and R.G. Ruddell (2005) Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Seminars in Liver Disease 25, 433-449

30 C. Camaschella (2000) The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nature Genetics 25, 14-15

31 M. Chloupkova , A.S. Zhang and C.A. Enns (2010) Stoichiometries of transferrin receptors 1 and 2 in human liver. Blood Cells Molecules and Diseases 44, 28-33

32 H. Kawabata (2000) Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. Journal of Biological Chemistry 275, 16618-16625

33 R.E. Fleming (2002) Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proceedings of the National Academy of Sciences of the United States of America 99, 10653-10658

34 H. Kawabata (2005) Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 105, 376-381

35 E. Nemeth (2005) Hepcidin is decreased in TFR2 hemochromatosis. Blood 105, 1803-1806

36 A. Pietrangelo (2005) Non-HFE hemochromatosis. Seminars in Liver Disease 25, 450-460

37 D.F. Wallace (2009) Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 50, 1992-2000

38 M. De Gobbi (2002) Natural history of juvenile haemochromatosis. British Journal of Haematology 117, 973-979

39 G. Papanikolaou (2004) Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nature Genetics 36, 77-82

40 A. Roetto (2003) Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nature Genetics 33, 21-22

43 L.P. Yang , S.J. Keam and G.M. Keating (2007) Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs 67, 2211-2230

44 E. Vichinsky (2008) Clinical application of deferasirox: practical patient management. American Journal of Hematology 83, 398-402

45 H. Li (2010) Transferrin therapy ameliorates disease in beta-thalassemic mice. Nature Medicine 16, 177-182

47 V.R. Gordeuk (2002) African iron overload. Seminars in Hematology 39, 263-269

48 R.L. Hamill , J.C. Woods and B.A. Cook (1991) Congenital atransferrinemia. A case report and review of the literature. American Journal of Clinical Pathology 96, 215-218

49 H. Morita (1995) Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Annals of Neurology 37, 646-656

50 P.F. Whitington (2007) Neonatal hemochromatosis: a congenital alloimmune hepatitis. Seminars in Liver Disease 27, 243-250

51 Y. Deugnier and B. Turlin (2007) Pathology of hepatic iron overload. World Journal of Gastroenterology 13, 4755-4760

52 R.P. Sarkany (2001) The management of porphyria cutanea tarda. Clinical Experimental Dermatology 26, 225-232

53 C. Hutchinson (2008) Post-prandial iron absorption in humans: comparison between HFE genotypes and iron deficiency anaemia. Clinical Nutrition 27, 258-263

55 M. Cazzola (1983) Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Human Genetics 65, 149-154

56 K.R. Bridle (2003) Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 361, 669-673

57 M.V. Spasic (2008) Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metabolism 7, 173-178

58 M. Vujic Spasic (2007) Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood 109, 4511-4517

59 J.L. Babitt (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nature Genetics 38, 531-539

60 D. Chen , M. Zhao and G.R. Mundy (2004) Bone morphogenetic proteins. Growth Factors 22, 233-241

61 Y. Xia (2008) Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 111, 5195-5204

62 J. Truksa (2009) Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6. British Journal of Haematology 147, 571-581

63 R.H. Wang (2005) A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metabolism 2, 399-409

64 K. Mleczko-Sanecka (2010) SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood 115, 2657-2665

65 J.L. Babitt (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. Journal of Clinical Investigation 117, 1933-1939

66 B. Andriopoulos Jr. (2009) BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nature Genetics 41, 482-487

67 D. Meynard (2009) Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nature Genetics 41, 478-481

68 L. Kautz (2008) Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112, 1503-1509

69 D.H. Lee (2010) Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis. Blood 115, 3136-3145

70 A.S. Zhang (2009) Hemojuvelin-neogenin interaction is required for bone morphogenic protein-4-induced hepcidin expression. Journal of Biological Chemistry 284, 22580-22589

71 X. Du (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320, 1088-1092

72 L. Lin , Y.P. Goldberg and T. Ganz (2005) Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106, 2884-2889

73 L. Silvestri , A. Pagani and C. Camaschella (2008) Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 111, 924-931

74 A.S. Zhang (2007) Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. Journal of Biological Chemistry 282, 12547-12556

75 A.R. Folgueras (2008) Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112, 2539-2545

76 K.E. Finberg (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nature Genetics 40, 569-571

77 F. Guillem (2008) Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency. Blood 112, 2089-2091

78 J.C. Chambers (2009) Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nature Genetics 41, 1170-1172

79 S.K. Ganesh (2009) Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nature Genetics 41, 1191-1198

80 T. Tanaka (2010) A genome-wide association analysis of serum iron concentrations. Blood 115, 94-96

81 L. Silvestri (2008) The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metabolism 8, 502-511

82 K.E. Finberg (2010) Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 115, 3817-3826

83 D.M. Frazer (2004) Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis. Gut 53, 1509-1515

84 C. Peyssonnaux (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). Journal of Clinical Investigation 117, 1926-1932

85 T. Tanno (2009) Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114, 181-186

86 T. Tanno (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Medicine 13, 1096-1101

87 J. Kanda (2008) Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 93, 1550-1554

89 J.J. Ross (2001) Twisted gastrulation is a conserved extracellular BMP antagonist. Nature 410, 479-483

90 G. Nicolas (2002) The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. Journal of Clinical Investigation 110, 1037-1044

91 N. Agarwal and J.T. Prchal (2009) Anemia of chronic disease (anemia of inflammation). Acta Haematologica 122, 103-108

92 D.M. Wrighting and N.C. Andrews (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204-3209

93 S.J. Wilkins (2006) Iron metabolism in the hemoglobin-deficit mouse: correlation of diferric transferrin with hepcidin expression. Blood 107, 1659-1664

94 H. Huebers (1985) Molecular advantage of diferric transferrin in delivering iron to reticulocytes: a comparative study. Proceedings Proceedings of the Society for Experimental Biology and Medicine 179, 222-226

96 D.A. Weinstein (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100, 3776-3781

97 M.B. Johnson and C.A. Enns (2004) Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 104, 4287-4293

98 J. Gao (2009) Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metabolism 9, 217-227

99 G. Ramey , J.C. Deschemin and S. Vaulont (2009) Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica 94, 765-772

100 A.P. West Jr (2001) Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. Journal of Molecular Biology 313, 385-397

101 P.J. Schmidt (2008) The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metabolism 7, 205-214

102 N.C. Andrews (2008) Forging a field: the golden age of iron biology. Blood 112, 219-230

103 A. Calzolari (2006) TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. Journal of Cell Science 119, 4486-4498

104 V. Niederkofler , R. Salie and S. Arber (2005) Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. Journal of Clinical Investigation 115, 2180-2186

106 H.K. Bayele , H. McArdle and S.K. Srai (2006) Cis and trans regulation of hepcidin expression by upstream stimulatory factor. Blood 108, 4237-4245

107 K. Bridle (2006) Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcoholism: Clinical and Experimental Research 30, 106-112

108 D.D. Harrison-Findik (2006) Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. Journal of Biological Chemistry 281, 22974-22982

109 J.M. Flanagan , H. Peng and E. Beutler (2007) Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcoholism: Clinical and Experimental Research 31, 138-143

110 H.K. Bayele and S.K. Srai (2009) Regulatory variation in hepcidin expression as a heritable quantitative trait. Biochemical and Biophysical Research Communications 384, 22-27

111 M. Andreani (2009) Association of hepcidin promoter c.-582 A > G variant and iron overload in thalassemia major. Haematologica 94, 1293-1296

112 A. Piperno (2007) Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 110, 4096-4100

113 B.A. van Dijk (2008) Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. British Journal of Haematology 142, 979-985

114 T. Knittel (1997) Bone morphogenetic protein-6 is expressed in nonparenchymal liver cells and upregulated by transforming growth factor-beta 1. Experimental Cell Research 232, 263-269

115 I. Theurl (2008) Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 111, 2392-2399

116 G. Nicolas (2003) Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nature Genetics 34, 97-101

117 A.H. Laftah (2004) Effect of hepcidin on intestinal iron absorption in mice. Blood 103, 3940-3944

118 B. Chung (2009) Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1 macrophages and intestinal Caco-2 cells. Journal of Nutrition 139, 1457-1462

119 E. Nemeth (2010) Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Advances in Hematology 2010, 750643, doi: 10.1155/2010/750643

120 P.N. Paradkar (2008) Iron depletion limits intracellular bacterial growth in macrophages. Blood 112, 866-874

121 J. Gao (2010) Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice. Blood 115, 3374-3381

122 B.J. Sasu Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115, 3616-3624

123 S. Ludwiczek (2007) Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nature Medicine 13, 448-454

124 G.Y. Oudit (2003) L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nature Medicine 9, 1187-1194

125 K. Sugishita (2009) A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction. International Heart Journal 50, 829-838

126 T. Ganz (2008) Immunoassay for human serum hepcidin. Blood 112, 4292-4297

127 N. Grebenchtchikov (2009) High-sensitive radioimmunoassay for human serum hepcidin. British Journal of Haematology 146, 317-325

128 M. Busbridge (2009) Development of a novel immunoassay for the iron regulatory peptide hepcidin. British Journal of Biomedical Science 66, 150-157

129 D.G. Ward (2008) SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Science 6, 28

130 E. Kemna (2005) Novel urine hepcidin assay by mass spectrometry. Blood 106, 3268-3270

131 A.T. Murphy (2007) Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 110, 1048-1054

132 H. Li (2009) Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. Journal of Pharmacological and Toxicological Methods 59, 171-180

133 J.J. Kroot (2009) Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 94, 1748-1752

134 T. Iqbal (2009) Is iron overload in alcohol-related cirrhosis mediated by hepcidin? World Journal of Gastroenterology 15, 5864-5866

135 H.P. Peters (2010) Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology, Dialysis, Transplantation 25, 848-853

136 M. van Deuren , J.J. Kroot and D.W. Swinkels (2009) Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist. Haematologica 94, 1297-1300

137 M.F. Young (2009) Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women. American Journal of Clinical Nutrition 89, 533-538

G. Weiss (2010) Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nature Reviews Gastroenterology and Hepatology 7, 50-58

A. Pietrangelo (2010) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139, 393-408

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 11 *
Loading metrics...

Abstract views

Total abstract views: 124 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 28th May 2017. This data will be updated every 24 hours.